https://wiki.cakele.iodatalabs.dev/index.php?action=history&feed=atom&title=DGI%3AZNS-Infektionen%2FNosokomiale_Ventrikulitis_und_Meningitis%2FTherapie%2FErregerspezifische_Therapie
DGI:ZNS-Infektionen/Nosokomiale Ventrikulitis und Meningitis/Therapie/Erregerspezifische Therapie - Revision history
2026-06-11T00:22:11Z
Revision history for this page on the wiki
MediaWiki 1.41.5
https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:ZNS-Infektionen/Nosokomiale_Ventrikulitis_und_Meningitis/Therapie/Erregerspezifische_Therapie&diff=6305&oldid=prev
imported>Fuhrmanns at 19:44, 9 August 2021
2021-08-09T19:44:27Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 19:44, 9 August 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">=== <span class="mw-headline" id="Erregerspezifische_Therapie.5B1.5D.5B2.5D" style="box-sizing: inherit;"><span class="ve-pasteProtect" data-ve-attributes="{&quot;style&quot;:&quot;font-size:13.5pt;\nmso-fareast-font-family:\&quot;Times New Roman\&quot;;mso-bidi-font-family:Calibri;\nmso-bidi-theme-font:minor-latin;mso-ansi-language:DE&quot;}" style="box-sizing: inherit; font-size: 13.5pt;">Erregerspezifische Therapie</span></span><ref>Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Michael Scheld W, van de Beek D, Bleck TP, Garton HJ, Zunt JR: 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis 2017; 64: e34–e65</ref><ref>Ambulant erworbene bakterielle (eitrige) Meningoenzephalitis im Erwachsenenalter, AWMF-Registernummer: 030/089 [<nowiki>https://www.awmf.org/leitlinien/detail/ll/030-089.html</nowiki></ref> ===</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{| class="wikitable" style="box-sizing: inherit; border-collapse: collapse; border-spacing: 0px; background-color: rgb(248, 249, 250); font-size: 14px; color: rgb(34, 34, 34); margin: 1em 0px; border: 1px solid rgb(162, 169, 177);"</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>{| class="wikitable" style="box-sizing: inherit; border-collapse: collapse; border-spacing: 0px; background-color: rgb(248, 249, 250); font-size: 14px; color: rgb(34, 34, 34); margin: 1em 0px; border: 1px solid rgb(162, 169, 177);"</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>! style="background-color:rgb(234, 236, 240);text-align:center;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Erreger</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>! style="background-color:rgb(234, 236, 240);text-align:center;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Erreger</div></td></tr>
<!-- diff cache key mediawiki:diff:1.41:old-6304:rev-6305:php=table -->
</table>
imported>Fuhrmanns
https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:ZNS-Infektionen/Nosokomiale_Ventrikulitis_und_Meningitis/Therapie/Erregerspezifische_Therapie&diff=6304&oldid=prev
imported>Maximilian.schons@uk-koeln.de: Maximilian.schons@uk-koeln.de verschob die Seite DGI:Nosokomiale Ventrikulitis und Meningitis/Therapie/Erregerspezifische Therapie nach DGI:ZNS-Infektionen/Nosokomiale Ventrikulitis und Meningitis/Therapie/Erregerspezifische Therapie: Texterset…
2021-08-03T07:40:44Z
<p>Maximilian.schons@uk-koeln.de verschob die Seite <a href="/index.php/DGI:Nosokomiale_Ventrikulitis_und_Meningitis/Therapie/Erregerspezifische_Therapie" title="DGI:Nosokomiale Ventrikulitis und Meningitis/Therapie/Erregerspezifische Therapie">DGI:Nosokomiale Ventrikulitis und Meningitis/Therapie/Erregerspezifische Therapie</a> nach <a href="/index.php/DGI:ZNS-Infektionen/Nosokomiale_Ventrikulitis_und_Meningitis/Therapie/Erregerspezifische_Therapie" title="DGI:ZNS-Infektionen/Nosokomiale Ventrikulitis und Meningitis/Therapie/Erregerspezifische Therapie">DGI:ZNS-Infektionen/Nosokomiale Ventrikulitis und Meningitis/Therapie/Erregerspezifische Therapie</a>: Texterset…</p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 07:40, 3 August 2021</td>
</tr><tr><td colspan="4" class="diff-notice" lang="en"><div class="mw-diff-empty">(No difference)</div>
</td></tr>
<!-- diff cache key mediawiki:diff:1.41:old-6303:rev-6304 -->
</table>
imported>Maximilian.schons@uk-koeln.de
https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:ZNS-Infektionen/Nosokomiale_Ventrikulitis_und_Meningitis/Therapie/Erregerspezifische_Therapie&diff=6303&oldid=prev
imported>Brinkery: Die Seite wurde neu angelegt: „=== <span class="mw-headline" id="Erregerspezifische_Therapie.5B1.5D.5B2.5D" style="box-sizing: inherit;"><span class="ve-pasteProtect" data-ve-attributes="{&q…“
2021-07-31T09:14:39Z
<p>Die Seite wurde neu angelegt: „=== <span class="mw-headline" id="Erregerspezifische_Therapie.5B1.5D.5B2.5D" style="box-sizing: inherit;"><span class="ve-pasteProtect" data-ve-attributes="{&q…“</p>
<p><b>New page</b></p><div>=== <span class="mw-headline" id="Erregerspezifische_Therapie.5B1.5D.5B2.5D" style="box-sizing: inherit;"><span class="ve-pasteProtect" data-ve-attributes="{&quot;style&quot;:&quot;font-size:13.5pt;\nmso-fareast-font-family:\&quot;Times New Roman\&quot;;mso-bidi-font-family:Calibri;\nmso-bidi-theme-font:minor-latin;mso-ansi-language:DE&quot;}" style="box-sizing: inherit; font-size: 13.5pt;">Erregerspezifische Therapie</span></span><ref>Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Michael Scheld W, van de Beek D, Bleck TP, Garton HJ, Zunt JR: 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis 2017; 64: e34–e65</ref><ref>Ambulant erworbene bakterielle (eitrige) Meningoenzephalitis im Erwachsenenalter, AWMF-Registernummer: 030/089 [<nowiki>https://www.awmf.org/leitlinien/detail/ll/030-089.html</nowiki></ref> ===<br />
{| class="wikitable" style="box-sizing: inherit; border-collapse: collapse; border-spacing: 0px; background-color: rgb(248, 249, 250); font-size: 14px; color: rgb(34, 34, 34); margin: 1em 0px; border: 1px solid rgb(162, 169, 177);"<br />
! style="background-color:rgb(234, 236, 240);text-align:center;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Erreger<br />
! style="background-color:rgb(234, 236, 240);text-align:center;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Standardtherapie<br />
! style="background-color:rgb(234, 236, 240);text-align:center;box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Alternativtherapie<br />
|- style="box-sizing: inherit;"<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Enterobacterales (z.B. ''Klebsiella'' spp''.'', ''E. coli'')<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Cefotaxim/Ceftriaxon<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Cefepim, Meropenem, Ciprofloxacin<br />
|- style="box-sizing: inherit;"<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Enterobacterales mit induzierbaren AmpC-Betalactamasen (z.B. ''Enterobacter cloacae'') oder <span class="mw-lingo-term" data-lingo-term-id="ae017919181d2041ce8454e856e5c522" data-hasqtip="16" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;">ESBL</span>-Bildner<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Meropenem<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Ciprofloxacin<br />
|- style="box-sizing: inherit;"<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |''Pseudomonas aeruginosa''<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Ceftazidim, Meropenem, Cefepim, ggf. jeweils in Kombination mit FosfomycinColistin (nur bei nachgewiesener Multiresistenz, i.v.+<span class="mw-lingo-term" data-lingo-term-id="acad626dfc19bbcc1906a927d63473b2" data-hasqtip="17" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;">i.t.</span>)<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Aztreonam oder Ciprofloxacin<br />
|- style="box-sizing: inherit;"<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |''Acinetobacter baumanii''<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Meropenem<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Colistin (i.v.+<span class="mw-lingo-term" data-lingo-term-id="acad626dfc19bbcc1906a927d63473b2" data-hasqtip="18" style="box-sizing: inherit; border-bottom: 1px dotted rgb(187, 187, 255); cursor: default;">i.t.</span>)<br />
|- style="box-sizing: inherit;"<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |''Staphylococcus'' spp. (Methicillin-empfindlich)<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Flucloxacillin ggf. PLUS Fosfomycin, Rifampicin oder Linezolid<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Vancomycin<br />
|- style="box-sizing: inherit;"<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |''Staphylococcus'' spp. (Methicillin-resistent)<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Vancomycin ggf. PLUS Fosfomycin, Rifampicin oder Linezolid<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Linezolid<br />
|- style="box-sizing: inherit;"<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |''Candida'' spp.<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Liposomales Amphotericin B ggf. PLUS Flucytosin<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Voriconazol, bei ''C. albicans'': Fluconazol<br />
|- style="box-sizing: inherit;"<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |''Aspergillus'' spp.<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Voriconazol<br />
| style="box-sizing:inherit;padding:0.2em 0.4em;border:1px solid rgb(162, 169, 177);" |Liposomales Amphotericin B, Posaconazol<br />
|}<br />
Bei Carbapenem-resistenten Gram-negativen Erregern sollte eine ergänzende intrathekale Therapie erfolgen. Für dieses Therapieregime konnte eine signifikante Reduktion der Sterblichkeit gezeigt werden<ref> Karvouniaris M, Brotis AG, Tsiamalou P, Fountas KN: The Role of Intraventricular Antibiotics in the Treatment of Nosocomial Ventriculitis/Meningitis from Gram-Negative Pathogens: A Systematic Review and Meta-Analysis. World Neurosurg 2018; 120:e637-e650</ref>. Diese Erkenntnisse konnten noch nicht in die aktuellen Leitlinien aufgenommen werden.</div>
imported>Brinkery